language flag

English

  • language flag

    English

  • language flag

    German

  • language flag

    Italian

  • language flag

    Spanish

Therakos Logo - Dark
Languages:
Therakos e-learning platform

Contact us

Our multi-lingual Customer Service Team are available as follows:

Customer Service Team from 9am to 6pm, Monday to Friday (GMT+1)

Technical and Clinical Service Team from 8am to 5pm, Monday to Friday (GMT+1)

TECHNICAL AND CLINICAL SUPPORT

For enquiries relating to technical and clinical support please contact the hotline at:
INTERNATIONAL TOLL-FREE: 00800 84372567 (Accessible from most countries in Europe and The Middle East)

Support
in English:

  • +44 154 860 0009

    0808 238 6011
    (Toll-Free within the UK)

  • +44 208 338 0479

  • ecphelp@therakos.com
    (For enquiries only)

Unterstützung
auf Deutsch:

  • +49 32 221 093 619

    0800 181 1715
    (Gebührenfreie Telefonnummer von Deutschland aus)

  • +49 61 097 009 318

  • ecphelp@therakos.com
    (Nur für Informationsanfragen)

Support
en français:

Supporto
in italiano:

  • +39 05 1042 0666

    800 149 844
    (Numero verde gratuito dall’Italia)

  • ecphelp@therakos.com
    (Solo per richiesta di informazioni)

Asistencia
en español:

Product orders, deliveries & invoicing

For enquiries relating to product orders, deliveries or invoicing please contact us at:

Support
in English:

  • +44 1784 614060

    0800 0698136
    (Toll-Free within the UK)

  • +44 203 7441022

  • Email Us

Unterstützung
auf Deutsch:

  • +49 6996759138

    0800 723 9486
    (Gebührenfreie Telefonnummer von Deutschland aus)

  • +49 69 5060 6793 /
    +49 69 5060 6794

  • Email Us

Support
en français:

  • +33 18 626 0833

    080 508 2214
    (Appel gratuit depuis la France)

  • +33 18 020 6913

  • Email Us

Supporto
in italiano:

  • +39 06 9480 0373

    800 684 170
    (Numero verde gratuito dall’Italia)

  • +39 06 9318 8019

  • Email Us

Asistencia
en español:

For billing enquiries please contact CritCareTKS-accountsreceivableEU@mnk.com

ADVERSE EVENTS

To report an adverse event please contact us at:
INTERNATIONAL FREEPHONE: 00800 84372567 (Available from most countries in Europe and Middle East and Africa)

Support
in English:

  • +44 154 860 0009

    Within the UK:
    0808 238 6011

Unterstützung
auf Deutsch:

  • +49 32 221 093 619

    Innerhalb Deutschland:
    0800 1811715

Support
en français:

  • +33 18 288 0867

Supporto
in italiano:

  • +39 051 042 0666

    All’interno dell’Italia:
    800 149 844

Asistencia
en español:

  • +34 932 20 2094

    Dentro de España:
    800 600 798

MEDICAL INFORMATION REQUEST

For medical enquiries relating to Mallinckrodt products please contact us at medinfo@mnk.com

GENERAL
ENQUIRIES

You can get in touch with us by using the form or calling us at:

  • +44 1784 614060

This request form is provided for your convenience to submit an enquiry directly to Therakos. This form is not intended to be used to report a product complaint, adverse event or to request immediate assistance with a patient treatment. No patient identifiable information should ever be included in this form.

Name
*Email
Phone:
Country:
*Message:
You are leaving the THERAKOS.EU website.
Therakos does not review or control the content of non-Therakos websites, and this hyperlink does not constitute an endorsement by Therakos of the site’s content. Therakos privacy procedures do not apply to the owners of a non-Therakos website.

Important Safety Information
For the TherakosTM Photopheresis
Procedure

Indications

The THERAKOSTM CELLEXTM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOSTM Photopheresis is contraindicated in:

  • Patients possessing a specific history of a light sensitive disease.
  • Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm3.
  • Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOSTM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

  • Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
  • Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
  • When prescribing and administering THERAKOSTM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

  • Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
  • Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
  • Treatment frequency exceeding labelling recommendations may result in anaemia.
  • Venous access carries a small risk of infection and pain.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

  • Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
  • Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
  • Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
  • Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

  • Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
  • Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
  • Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
  • Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.

This website is not intended for healthcare professionals based in US, France and Canada.

Please verify your status below.

I am a healthcare professional and

I am eligible to access this part of the website

I am not a healthcare professional.

I would like to return to the homepage

This website is not intended for residents
based in the US, France or Canada.

PLEASE CLICK HERE TO ENTER

If you are a French resident, please visit www.therakos.fr

Applications for the 2022 EIA are now closed.
The 2022 ECP Immunomodulation Investigator Award has been awarded to Professor Andrew Fisher, Professor of Respiratory Transplant Medicine at Newcastle University, and Honorary Consultant Respiratory and Transplant Physician at The Newcastle upon Tyne Hospitals NHS Foundation Trust's Institute of Transplantation. The objective of his project is to perform an in depth mechanistic assessment of Extracorporeal Photopheresis (ECP) treatment in patients suffering from Chronic lung Allograft Dysfunction (CLAD).

Full details are available on our press release page.

Copy the link to share with the HCP by clicking on the button below

 
THANK YOU FOR YOUR MESSAGE
We will take care of your request and get in contact with you soon
 
THANK YOU FOR YOUR APPLICATION
We can confirm we have received your submission.
 
AUTHORISATION

The Therakos e-learning platform wants to access the following information:

Your basic public profile
Your public email address

Please click the below button to authorise it

WELCOME TO THERAKOS.EU MY AREA
Forgot your password? Click Here
Not yet registered?
WELCOME TO THERAKOS.EU MY AREA
Forgot your password?